Hunter Perkins Capital Management LLC lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 448.6% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 214,550 shares of the company’s stock after purchasing an additional 175,442 shares during the period. Merck & Co., Inc. accounts for 3.3% of Hunter Perkins Capital Management LLC’s holdings, making the stock its 10th biggest position. Hunter Perkins Capital Management LLC’s holdings in Merck & Co., Inc. were worth $16,540,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in the stock. Flagship Private Wealth LLC bought a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $27,000. Financial Avengers Inc. bought a new position in Merck & Co., Inc. during the fourth quarter worth $28,000. Joseph P. Lucia & Associates LLC bought a new position in Merck & Co., Inc. during the fourth quarter worth $29,000. Curi Capital acquired a new position in shares of Merck & Co., Inc. in the fourth quarter valued at $29,000. Finally, Veritas Investment Partners UK Ltd. bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at about $30,000. 72.86% of the stock is owned by institutional investors and hedge funds.
MRK has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Merck & Co., Inc. in a report on Friday, February 5th. SVB Leerink decreased their target price on Merck & Co., Inc. from $103.00 to $102.00 and set an “outperform” rating on the stock in a research report on Friday. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Merck & Co., Inc. currently has an average rating of “Buy” and an average price target of $97.22.
Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 29th. The company reported $1.40 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.63 by ($0.23). Merck & Co., Inc. had a return on equity of 53.83% and a net margin of 24.33%. The firm had revenue of $12.08 billion for the quarter, compared to the consensus estimate of $12.71 billion. During the same period last year, the company posted $1.50 EPS. The business’s revenue was up .2% on a year-over-year basis. On average, analysts anticipate that Merck & Co., Inc. will post 5.9 EPS for the current fiscal year.
About Merck & Co., Inc.
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products.
See Also: How Does the Quiet Period Work?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.